Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2022

Q2 2022 biggest moves
  • BIIBBIIB

    Biogen

    New calls

    on 500K shares

  • IMGNIMGN

    IMMUNOGEN

    4.3× the shares

    now 1.4% of portfolio

  • GILDGILD

    Gilead Sciences

    2× the shares

    now 2.0% of portfolio

  • ORGOORGO

    Organogenesis

    Cut 47%

    now 0.4% of portfolio

71 changes in all

Top Holdings127 positions

Checking export access…
Activity:
??
GLAUKOS CORPDelisted
Bond
271.8M$324.5M6.7%——
5 qtrssince 2021-Q2
Increased
60
NUVL
NUVLDelisted

NUVALENT INC

19.3M$262.3M5.4%——
4 qtrssince 2021-Q3
Unchanged
0
VTRS

Viatris Inc.

20.7M$216.5M4.5%$14.06-37.99%
7 qtrssince 2020-Q4
Unchanged
0
AHCO

AdaptHealth Corp.

11.2M$201.2M4.1%$23.56-23.44%
11 qtrssince 2019-Q4
Decreased
0
NBIX

Neurocrine Biosciences, Inc.

2M$196.2M4.0%$95.11+2.49%
6 qtrssince 2021-Q1
Increased
67
??
INVITAE CORPDelisted
Bond
206.9M$163M3.4%——
8 qtrssince 2020-Q3
Unchanged
0
157.4M$133M2.7%——
8 qtrssince 2020-Q3
Unchanged
0
127.8M$117M2.4%——
1 qtr
New
78
??
NATERA INCDelisted
Bond
90.6M$111.9M2.3%——
5 qtrssince 2021-Q2
Unchanged
0
88.7M$111.8M2.3%——
2 qtrssince 2022-Q1
Unchanged
0
BIIB
BIIB
CALL

Biogen Inc.

500,000$102M2.1%———
New
—
52.5M$100.4M2.1%——
5 qtrssince 2021-Q2
Unchanged
0
SILK
SILKDelisted

SILK ROAD MEDICAL INC

2.7M$97.4M2.0%——
7 qtrssince 2020-Q4
Increased
63
144.5M$97.2M2.0%——
6 qtrssince 2021-Q1
Increased
66
GILD

Gilead Sciences, Inc.

1.6M$96M2.0%$52.26+2.53%
2 qtrssince 2022-Q1
Increased
76
??
NUVASIVE INCDelisted
Bond
97M$93.6M1.9%——
5 qtrssince 2021-Q2
Unchanged
0
81.6M$85M1.8%——
4 qtrssince 2021-Q3
Unchanged
0
DCPH
DCPHDelisted

DECIPHERA PHARMACEUTICALS IN

6.3M$82.2M1.7%——
11 qtrssince 2019-Q4
Increased
53
51.9M$76.5M1.6%——
8 qtrssince 2020-Q3
Unchanged
0
??
NUVASIVE INCDelisted
Bond
80M$71.7M1.5%——
6 qtrssince 2021-Q1
Unchanged
0
$4.8B
AUM
127
Positions
Q2 2022
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2021-Q1$4,758,345,000-5.95750963184%
2021-Q2$5,629,668,00018.3114717407%
2021-Q3$5,123,921,000-8.98360258545%
2021-Q4$4,767,581,000-6.95443977376%
2022-Q1$4,472,946,000-6.17996841585%
2022-Q2$4,848,381,0008.39346149048%
Activity profile
$ moved · Q2'22
New41%Increased35%Decreased13%Exited11%
Composition
Equity vs derivatives
Equity98%Puts0%Calls2%
Holding period
Avg 1.1 years
<1Q13%1-4Q31%1-2Y37%2Y+19%

Deerfield Management Company, L.P. manages $4.8B across 127 positions as of Q2 2022. Top holdings: GLAUKOS CORP (6.7%), NUVL (5.4%), VTRS (4.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
GLAUKOS CORP6.69%
NUVL5.41%
VTRS4.46%
AHCO4.15%
NBIX4.05%
INVITAE CORP3.36%
AERIE PHARMA2.74%
IONIS PHARMA2.41%
NATERA INC2.31%
SAREPTA THER2.31%
Other2.07%

Portfolio allocation by GICS sector

Sectors2
Healthcare76.77%
Unknown23.23%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used